From NASDAQ.:

Bayer’s Phase III studies OASIS 1 and 2 showed positive results for elinzanetant in reducing frequency and severity of vasomotor symptoms, meeting primary and key secondary endpoints with a consistent safety profile. The company plans to seek marketing authorizations for the treatment of moderate to severe vasomotor symptoms associated with menopause based on the OASIS studies. Results from the third Phase III study, OASIS 3, are expected soon. (RTTNews)

This news by Bayer on the positive results of elinzanetant in treating vasomotor symptoms in menopausal women is a significant development in the healthcare industry. The company plans to seek marketing authorizations based on the successful Phase III studies. Stay tuned for more updates on the OASIS 3 study. (RTTNews)



Read more: Bayer Reports Positive Results From Two Pivotal Phase III Studies For Elinzanetant